Tumor uptake of 64Cu-DOTA-trastuzumab correlates with HER2 status in patients with metastatic breast cancer
Abstract
1324 null Objectives null Patients with human epidermal growth factor receptor 2-positive (HER2+, i.e., IHC 3+ or 2+/FISH > 2.2) metastatic breast cancer routinely receive the anti-HER2 antibody trastuzumab plus chemotherapy. 64Cu-DOTA-trastuzumab/PET-CT has high tumor detection sensitivity in HER2+ patients [Bading, et al., JNM 2012;53 (Suppl 1):229P]. We are also imaging HER2- patients and present an initial comparison of tumor uptake between...
Paper Details
Title
Tumor uptake of 64Cu-DOTA-trastuzumab correlates with HER2 status in patients with metastatic breast cancer
Published Date
May 1, 2013
Volume
54
Pages
1324 - 1324
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History